Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D, Cross P, Hughes J, Gao G, Wilson JM, Propert K.

Hum Gene Ther. 2001 Jan 1;12(1):97-113. No abstract available.

PMID:
11177547
2.

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.

Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z; ASPECT Study Group.

Lancet Oncol. 2013 Aug;14(9):823-33. doi: 10.1016/S1470-2045(13)70274-2. Epub 2013 Jul 12.

PMID:
23850491
3.

A phase I trial of Ad.hIFN-beta gene therapy for glioma.

Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D.

Mol Ther. 2008 Mar;16(3):618-26. doi: 10.1038/sj.mt.6300396. Epub 2008 Jan 8.

4.

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.

Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW.

Cancer Res. 2004 Aug 15;64(16):5753-9.

5.

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses.

Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynelä K, Turunen M, Vanninen R, Lehtolainen P, Paljärvi L, Johansson R, Vapalahti M, Ylä-Herttuala S.

Hum Gene Ther. 2000 Nov 1;11(16):2197-205.

PMID:
11084677
6.

A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas.

Fine HA, Wen PY, Robertson M, O'Neill A, Kowal J, Loeffler JS, Black PM.

Clin Cancer Res. 1997 Mar;3(3):381-7.

7.

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.

Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Ylä-Herttuala S.

Mol Ther. 2004 Nov;10(5):967-72.

8.

A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.

Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J.

J Gene Med. 2008 Apr;10(4):329-39. doi: 10.1002/jgm.1160.

PMID:
18220319
9.
10.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

11.

Clinical development of experimental virus-mediated gene therapy for malignant glioma.

Rainov NG, Heidecke V.

Anticancer Agents Med Chem. 2011 Oct;11(8):739-47. Review.

PMID:
21707496
12.

[Brain tumor therapy using replication--competent virus vectors].

Todo T.

Nihon Rinsho. 2005 Sep;63 Suppl 9:504-9. Review. Japanese. No abstract available.

PMID:
16201572
13.

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.

Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11313-8. Review.

14.

Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.

Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ.

Gene Ther. 2004 Apr;11(8):658-67.

PMID:
14973547
15.
16.

Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.

Chang JW, Lee H, Kim E, Lee Y, Chung SS, Kim JH.

Neurosurgery. 2000 Oct;47(4):931-8; discussion 938-9.

PMID:
11014433
17.

[Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].

Zhu JX, Li ZM, Geng FY, Fu Q, Guo CJ, Xiao YL, Zhang ZT, Li G.

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):709-12. Chinese.

PMID:
21122390
18.

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J.

Mol Ther. 2004 Nov;10(5):958-66.

19.

Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: cytocidal effect on glioma transplanted into nude mouse brain.

Yagi K, Hayashi Y, Ishida N, Ohbayashi M, Ohishi N, Mizuno M, Yoshida J.

Biochem Mol Biol Int. 1994 Jan;32(1):167-71.

PMID:
8012282
20.

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG.

Neuro Oncol. 2007 Jul;9(3):245-58. Epub 2007 May 23.

Supplemental Content

Support Center